Fluphenazine Long-Acting Injection Discontinued
Important update: Fluphenazine long-acting injection (Modecate®) discontinued. Learn about its prior uses, administration, and transition guidance for schizophrenia management.
Fluphenazine long-acting injection, also known as Modecate®, has been discontinued in many markets, prompting healthcare providers to transition patients to alternative therapies for schizophrenia and related psychotic disorders. This depot formulation was previously valued for its convenience in maintaining symptom control without daily oral dosing.
About fluphenazine long-acting injection
Fluphenazine long-acting injection belonged to the class of typical antipsychotics, primarily used for long-term management of schizophrenia and other psychotic disorders in adults. It was particularly beneficial for patients who struggled with adherence to daily oral medications.
| Type of medicine | An antipsychotic injection |
|---|---|
| Used for | Maintenance of symptom control in adults with schizophrenia and other similar mental health problems |
| Also called | Fluphenazine decanoate; Modecate® (discontinued) |
| Available as | Long-acting ‘depot’ injection (now discontinued) |
Antipsychotics like fluphenazine work by blocking dopamine receptors in the brain, helping to reduce hallucinations, delusions, and disorganized thinking associated with schizophrenia. The long-acting depot injection released the drug slowly over 2-5 weeks, ensuring steady levels and improving compliance compared to tablets.
A key advantage was its role in maintenance therapy after initial symptom stabilization with oral forms. Patients typically transitioned to injections once acute symptoms were controlled, with dosing every 2-5 weeks tailored to individual response.
Prior to use, clinicians assessed suitability, avoiding it in patients with conditions like epilepsy, depression, Parkinson’s disease, glaucoma, thyroid disorders, or myasthenia gravis. History of jaundice or severe allergies also contraindicated its use.
How fluphenazine long-acting injection was given
The injection was administered by a healthcare professional, usually a doctor or nurse, into the gluteal muscle (buttocks). For first-time users, a test dose of 12.5-25 mg was given 4-7 days before the full dose to check tolerance, minimizing risks like hypersensitivity.
Standard initial dosing ranged from 12.5 mg to 25 mg intramuscularly, with effects onset in 24-72 hours and peak antipsychotic action in 48-96 hours. Maintenance doses were adjusted based on response, often every 2-4 weeks, sometimes extending to 6 weeks in stable patients.
- Injection technique: Slow, deep injection into the upper outer quadrant of the gluteus maximus using a dry syringe and needle. Patients remained recumbent for 30 minutes post-injection to counter potential hypotension.
- Site rotation: Alternate injection sites to prevent irritation, abscesses, or tissue damage.
- Transition from oral: Patients often continued oral antipsychotics for 1-2 weeks after the first injection, as full effects took time to build.
Treatment was long-term to prevent relapse. Missing doses increased symptom return risk, so prompt rescheduling was advised. Smoking changes affected metabolism, requiring dose adjustments due to enzyme induction by tobacco.
Before surgeries or dental work, inform providers, as fluphenazine could interact with anesthetics or analgesics. Over-the-counter remedies needed pharmacist checks for compatibility.
Can fluphenazine long-acting injection cause problems?
Like all antipsychotics, fluphenazine carried risks of side effects, though not all patients experienced them. Common issues were manageable, while serious ones required immediate attention.
| Common side effects | How to manage |
|---|---|
| Pain at injection site | Usually short-lived; report redness, swelling, or lumps to doctor |
| Sleepiness, dizziness, blurred vision | Avoid driving or machinery until cleared |
| Dry mouth | Chew sugar-free gum or suck sweets |
| Muscle movements (dystonia, akathisia), shakiness | Contact doctor for possible dose adjustment or anticholinergics |
| Headache | Hydrate; use pharmacist-recommended painkillers; seek advice if persistent |
| Weight changes, nasal congestion, insomnia, agitation, confusion, sexual dysfunction, breast/menstrual changes, tachycardia, constipation, urinary issues | Discuss with doctor if troublesome |
Serious risks: Neuroleptic malignant syndrome (NMS) – rare but life-threatening, with symptoms like muscle rigidity, hyperthermia, confusion, sweating, tachycardia, incontinence. Seek emergency care immediately. Long-term use risked tardive dyskinesia (irreversible movements), pigmentary retinopathy, lens opacities, and skin pigmentation.
Other concerns included hypotension, cardiovascular effects (use caution in mitral insufficiency, pheochromocytoma), liver damage, and altered EEG/CSF findings. Extrapyramidal symptoms were common with typical antipsychotics like fluphenazine.
Full side effect lists were in manufacturer leaflets. Patients should report new or worsening symptoms promptly.
Discontinuation and Alternatives
Fluphenazine decanoate (Modecate®) discontinuation stems from manufacturing challenges and shifts toward atypicals with better tolerability profiles. Patients must transition under medical supervision to avoid relapse.
Alternatives include other depot antipsychotics like paliperidone palmitate (Invega Sustenna®), aripiprazole lauroxil (Aristada®), or risperidone (Risperdal Consta®), offering similar long-acting benefits with lower extrapyramidal risks.
- Transition tips: Gradual switch while overlapping with oral forms; monitor for efficacy and side effects.
- Oral options: Aripiprazole, olanzapine, quetiapine for non-adherent patients.
- Monitoring: Regular blood tests, weight checks, and metabolic screening recommended.
Do not abruptly stop; consult providers for personalized plans. Relapse risk rises without medication.
Frequently Asked Questions (FAQs)
What was fluphenazine long-acting injection used for?
It maintained symptom control in schizophrenia and similar psychoses, releasing slowly over 2-5 weeks.
Why was it discontinued?
Manufacturing discontinuation (e.g., Modecate® brand); alternatives now preferred for safety.
How often was the injection given?
Every 2-5 weeks, adjusted per response; test dose first for new users.
What if I miss an injection?
Reschedule ASAP; missing increases relapse risk.
Does smoking affect dosing?
Yes; starting/stopping smoking requires dose review due to metabolism changes.
Are there serious side effects?
Yes, like NMS or tardive dyskinesia; report muscle stiffness, fever, or unusual movements immediately.
What alternatives exist post-discontinuation?
Other depots like paliperidone or aripiprazole; discuss with your doctor.
Patient Guidance Post-Discontinuation
With fluphenazine depot unavailable, proactive management is key. Work with your psychiatrist to select alternatives matching your needs—considering side effect profiles, dosing frequency, and lifestyle. Long-acting injectables remain vital for adherence-challenged patients, reducing hospitalization risks.
Lifestyle supports treatment: balanced diet, exercise, avoiding alcohol/drugs, therapy integration. Regular follow-ups ensure stability.
For dental/surgical procedures, always disclose recent antipsychotic use.
References
- Fluphenazine long-acting injection – Patient.info — Patient.info. 2023. https://patient.info/medicine/fluphenazine-long-acting-injection-discontinued
- FLUPHENAZINE DECANOATE – FDA Label — U.S. Food and Drug Administration. 2010-06-25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/071413s019lbl.pdf
- Fluphenazine – National Alliance on Mental Illness — NAMI. 2024. https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/fluphenazine/
- Prolixin Decanoate – Drug Summary — PDR.net. 2024. https://www.pdr.net/drug-summary/Fluphenazine-Decanoate-fluphenazine-decanoate-1262
- Fluphenazine depot injection – Cleveland Clinic — Cleveland Clinic. 2023-10-01. https://my.clevelandclinic.org/health/drugs/20298-fluphenazine-depot-injection
Similar Articles
Read full bio of Sneha Tete
